Combined endocrine and targeted therapy in luminal breast cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries: global Cancer Statistics 2018. CA Cancer J Clin [Internet] 2018 [ cited 2018 Oct 11]; Available from: 68 6 394–424
   PubMed Web of Science ®Google Scholar
• Winters S, Martin C, Murphy D, et al. Breast cancer epidemiology, prevention, and screening [Internet]. In: Rakjumar Lakshmanaswamy, editors. Progress in molecular biology and translational science. Elsevier; 2017 cited 2020 May 26. p. 1–32. Available from https://linkinghub.elsevier.com/retrieve/pii/S1877117317301126
   Google Scholar
• Howlader N, Altekruse SF, Li CI, et al.US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.JNCI J Natl Cancer Inst Internet] 2014 [cited 2020 May 26];106(5). Available from.;() . https://doi.org/10.1093/jnci/dju055
   Google Scholar
• Savard M-F, Khan O, Hunt KK, et al. Redrawing the lines: the next generation of treatment in metastatic breast cancer. Am Soc Clin Oncol Educ Book. 2019:(39):e8–21
   Google Scholar
• Rugo HS, Vidula N, Ma C. Improving response to hormone therapy in breast cancer: new targets, new therapeutic options. Am Soc Clin Oncol Educ Book. 2016:(36):e40–54.
   Google Scholar
• Li A, Schleicher SM, Andre F, et al. Genomic alteration in metastatic breast cancer and its treatment. Am Soc Clin Oncol Educ Book. 2020;40(40):30–43.
   Google Scholar
• McDonnell DP. Connections and regulation of the human estrogen receptor. Science. 2002;296(5573):1642–1644.
   PubMed Web of Science ®Google Scholar
• Saha Roy S, Vadlamudi RK. Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer. 2012;2012:1–8.
   Google Scholar
• Yager JD, Davidson NE. Estrogen Carcinogenesis in Breast Cancer. N Engl J Med. 2006;354(3):270–282.
   PubMed Web of Science ®Google Scholar
• Jameera Begam A, Jubie S, Nanjan MJ. Estrogen receptor agonists/antagonists in breast cancer therapy: a critical review. Bioorg Chem. 2017;71:257–274.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Wood AJJ. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609–1618.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(8):1194–1220. .
   PubMed Web of Science ®Google Scholar
• Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)†. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(8):1634–1657. .
   PubMed Web of Science ®Google Scholar
• Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell. 2020;37(4):496–513.
   PubMed Web of Science ®Google Scholar
• Wang L, Guillen VS, Sharma N, et al. New class of Selective Estrogen Receptor Degraders (SERDs): expanding the toolbox of PROTAC Degrons. ACS Med Chem Lett. 2018;9(8):803–808. .
   PubMed Web of Science ®Google Scholar
• Song X, Chen J, Zhao M, et al. Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3. Proc Natl Acad Sci. 2016;113(18):4970–4975. .
   PubMed Web of Science ®Google Scholar
• Choi YJ, Anders L. Signaling through cyclin D-dependent kinases. Oncogene. 2014;33(15):1890–1903.
   PubMed Web of Science ®Google Scholar
• Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res. 2011;13(6):221.
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. .
   PubMed Web of Science ®Google Scholar
• Narita M, Nuñez S, Heard E, et al. Rb-Mediated heterochromatin formation and silencing of e2f target genes during cellular senescence. Cell. 2003;113(6):703–716. .
   PubMed Web of Science ®Google Scholar
• Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471–475. .
   PubMed Web of Science ®Google Scholar
• Spring LM, Wander SA, Zangardi M, et al. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep. 2019;21(3):25.
   PubMed Web of Science ®Google Scholar
• Cornell L, Wander SA, Visal T, et al. MicroRNA-Mediated suppression of the TGF-β pathway confers transmissible and reversible CDK4/6 inhibitor resistance. Cell Rep. 2019;26(10):2667–2680.e7.
   PubMed Web of Science ®Google Scholar
• Razavi P, Chang MT, Xu G, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34(3):427–438.e6. .
   PubMed Web of Science ®Google Scholar
• Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer. 2019;125(21):3714–3728.
   PubMed Web of Science ®Google Scholar
• Fanning SW, Greene GL. Next-generation ERα inhibitors for endocrine-resistant ER+ Breast Cancer. Endocrinology. 2019;160(4):759–769.
   PubMed Web of Science ®Google Scholar
• Gates LA, Gu G, Chen Y, et al. Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets. Oncogene. 2018;37(33):4581–4598. .
   PubMed Web of Science ®Google Scholar
• Harrod A, Fulton J, Nguyen VTM, et al. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene. 2017;36(16):2286–2296. .
   PubMed Web of Science ®Google Scholar
• Bjornsti M-A, Houghton PJ. The tor pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4(5):335–348.
   PubMed Web of Science ®Google Scholar
• Verret B, Cortes J, Bachelot T, et al. Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol. 2019;30:x12–20.
   PubMedGoogle Scholar
• Lee K, Guerrero-Zotano A, Hanker A, et al. Abstract GS6-06: a neoadjuvant trial with letrozole identifies PRR11 in the 17q23 amplicon as a mechanism of resistance to endocrine therapy in ER-positive breast cancer [Internet]. In: General session abstracts. Chicago, IL, USA: American Association for Cancer Research; 2020. cited 2020 Jun 25. p. GS6-06-GS6-06. Available fromhttp://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS19-GS6-06
   Google Scholar
• Pearson A, Proszek P, Pascual J, et al. Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance. Clin Cancer Res. 2020;26(3):608–622. .
   PubMed Web of Science ®Google Scholar
• Philpott C, Tovell H, Frayling IM, et al. The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics. 2017;11(1):13.
   PubMedGoogle Scholar
• Ross DS, Liu B, Schram AM, et al. Enrichment of kinase fusions in ESR1 wild type, metastatic breast cancer revealed by a systematic analysis of 4,854 patients. Ann Oncol. 2020 Aug;31(8):991-1000.
   Google Scholar
• Perez-Garcia J, Muñoz-Couselo E, Soberino J, et al. Targeting FGFR pathway in breast cancer. Breast. 2018;37:126–133.
   PubMed Web of Science ®Google Scholar
• Smyth LM, Piha-Paul SA, Won HH, et al. Efficacy and determinants of response to HER kinase inhibition in HER2 -mutant metastatic breast cancer. Cancer Discov. 2020;10(2):198–213. .
   PubMed Web of Science ®Google Scholar
• Zacksenhaus E, Liu JC, Jiang Z, et al. Transcription factors in breast cancer—lessons from recent genomic analyses and therapeutic implications [Internet]. In: Advances in protein chemistry and structural biology. Amsterdam: Elsevier; 2017. cited 2020 Jul 24. p. 223–273. Available fromhttps://linkinghub.elsevier.com/retrieve/pii/S1876162316300566
   Google Scholar
• Xu G, Chhangawala S, Cocco E, et al. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nat Genet. 2020;52(2):198–207. .
   PubMed Web of Science ®Google Scholar
• Alqahtani A, Choucair K, Ashraf M, et al. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA. 2019;5(3):FSO372. .
   PubMed Web of Science ®Google Scholar
• Abdel-Hafiz HA, Horwitz KB. Role of epigenetic modifications in luminal breast cancer. Epigenomics. 2015;7(5):847–862.
   PubMed Web of Science ®Google Scholar
• Fontes‑Sousa M, Amorim M, Salta S, et al. Predicting resistance to endocrine therapy in breast cancer: it’s time for epigenetic biomarkers (Review). Oncol Rep. Internet] 2019 [cited 2020 Jul 24];Available from… : http://www.spandidos-publications.com/10.3892/or.2019.6967
   PubMed Web of Science ®Google Scholar
• Shan M, Zhang L, Liu Y, et al. DNA methylation profiles and their diagnostic utility in BC. Dis Markers. 2019;2019:1–10.
   Web of Science ®Google Scholar
• Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26(37):5420–5432.
   PubMed Web of Science ®Google Scholar
• Damaskos C, Valsami S, Kontos M, et al. Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer. Anticancer Res. 2017;37(1):35–46. .
   PubMed Web of Science ®Google Scholar
• Shaheenash S, Brzozowski K et al. Efficacy of CDK4/6i in the visceral crisis setting: result from a real-world database. Abstract 1047 ASCO 2021 Poster Session.
   Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med. 2012;366(6):520–529. .
   PubMed Web of Science ®Google Scholar
• Bachelot T, Bourgier C, Cropet C, et al. Randomized phase ii trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30(22):2718–2724. .
   PubMed Web of Science ®Google Scholar
• Kornblum N, Zhao F, Manola J, et al. Randomized phase ii trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(16):1556–1563.
   PubMed Web of Science ®Google Scholar
• Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25(12):2357–2362. .
   PubMed Web of Science ®Google Scholar
• Royce M, Villanueva C, Ozguroglu M, et al. BOLERO-4: phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC). Ann Oncol Internet] 2016 [cited 2018 Jul 3];27(suppl_6).vi68. Available from. http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdw365.01/2798961/BOLERO4-Phase-2-trial-of-firstline-everolimus-EVE.
   Google Scholar
• Jerusalem G, De Boer RH, Hurvitz S, et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor–positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncol. 2018 Oct 1;4(10):1367-1374.
   Web of Science ®Google Scholar
• Rugo HS, Seneviratne L, Beck JT, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017;18(5):654–662. .
   PubMed Web of Science ®Google Scholar
• Giridhar KV, Choong GM, Leon-Ferre RA, et al.: Clinical management of metastatic breast cancer after CDK4/6 inhibitors: a retrospective single-institution study. 2018 San Antonio Breast Cancer Symposium. Abstract P6-18-09, San Antonio, Texas, USA. Presented December 8, 2018.
   Google Scholar
• Cook M, Al Rabadi L, Mitri ZI, et al.: Everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer patients previously treated with CDK4/6 inhibitor-based therapies. 2019 ASCO Annual Meeting. Abstract 1058, Chicago, IL, USA. Presented June 2, 2019.
   Google Scholar
• Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: american society of clinical oncology guideline. J Clin Oncol Internet] 2016 [cited 2016 Jun 26];Available from. ;34(25):3069–3103. .
   Web of Science ®Google Scholar
• Xu B Zhang Q Zhang P et al. Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): a multicenter, randomized, phase 3 study. ASCO 2021 oral presentation, Chicago IL USA.
   Google Scholar
• Rugo HS, Diéras V, Gelmon KA, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018;29(4):888–894. .
   PubMed Web of Science ®Google Scholar
• Cristofanilli et al Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): updated analyses from PALOMA-3. ASCO 2021 oral presentation, Chicago IL USA.
   Google Scholar
• Malorni L, Curigliano G, Minisini AM, et al. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: tREnd trial. Ann Oncol. 2018;29(8):1748–1754. .
   PubMed Web of Science ®Google Scholar
• Park YH, Kim T-Y, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2019;20(12):1750–1759. .
   PubMed Web of Science ®Google Scholar
• Abstract GS2-07: results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): a phase 3 trial of Miguel Martín, Christoph Zielinski, Manuel Ruíz-Borrego, Eva Carrasco, Eva Ciruelos,et alPalbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs) https://doi.org/10.1158/1538-7445.SABCS19-GS2-07 Published February 2020.
   Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748. .
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol Internet] 2018 [cited 2018 May 28];Available from. ;29(7):1541–1547. .
   Web of Science ®Google Scholar
• Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–915. .
   PubMed Web of Science ®Google Scholar
• Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–316. .
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472. .
   PubMed Web of Science ®Google Scholar
• Slamon DJ Neven P Chia SKL et al. Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB) ASCO 2021 oral presentation, Chicago IL USA.
   Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638–3646. .
   PubMed Web of Science ®Google Scholar
• Sledge GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884. .
   PubMed Web of Science ®Google Scholar
• Di Leo A, O’Shaughnessy J, Sledge GW, et al. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. Npj Breast Cancer. 2018;4(1):41. .
   PubMed Web of Science ®Google Scholar
• Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Cancer. 2019;5(1):5.
   PubMedGoogle Scholar
• Sledge GW, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a Randomized clinical trial. JAMA Oncol. 2020;6(1):116. .
   PubMed Web of Science ®Google Scholar
• Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A phase ii study of abemaciclib, a CDK4 and CDK6 Inhibitor, as a single agent, in patients with refractory HR + /HER2 − metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218–5224. .
   PubMed Web of Science ®Google Scholar
• Hamilton E, Cortés J, Ozyilkan O. et al. nextMONARCH: final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer ESMO 2020 Oral Presentation, Madrid Spain.
   Google Scholar
• Olson SR, DeLoughery TG, Shatzel JJ. Cyclin-dependent kinase inhibitor–associated thromboembolism. JAMA Oncol. 2019;5(2):141.
   PubMed Web of Science ®Google Scholar
• Llombart-Cussac A, Pérez-García JM, Bellet M, et al. PARSIFAL: a randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer. J Clin Oncol. 2020;38(15_suppl):1007. .
   Web of Science ®Google Scholar
• Bidard FC, Callens C, Dalenc F, et al., Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: an exploratory analysis of the PADA-1 trial. J Clin Oncol. 2020;38(15_suppl):1010. .
   Web of Science ®Google Scholar
• Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase iii trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252–1260. .
   PubMed Web of Science ®Google Scholar
• Delaloge S, Pérol D, Courtinard C, et al. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(9):1725–1732. .
   PubMed Web of Science ®Google Scholar
• Corona SP, Generali D. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. Drug Des Devel Ther. 2018;12:321–330.
   PubMed Web of Science ®Google Scholar
• Sumi NJ, Kuenzi BM, Knezevic CE, et al. Chemoproteomics reveals novel protein and lipid kinase targets of clinical CDK4/6 inhibitors in lung cancer. ACS Chem Biol. 2015;10(12):2680–2686.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. .
   PubMed Web of Science ®Google Scholar
• Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res Internet] 2016 [cited 2016 Feb 17];18(1). Available from http://breast-cancer-research.com/content/18/1/17
   Google Scholar
• Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet Lond Engl. 2016;388(10063):2997–3005. .
   PubMed Web of Science ®Google Scholar
• Mehta RS, Barlow WE, Albain KS, et al. Overall survival with fulvestrant plus anastrozole in metastatic breast cancer. N Engl J Med. 2019;380(13):1226–1234. .
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol Internet] 2016 [cited 2016 Mar 24];Available from ;http://linkinghub.elsevier.com/retrieve/pii/S1470204515006130
   Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514–524. .
   PubMed Web of Science ®Google Scholar
• André F, Ciruelos E, Rubovszky G, et al., Alpelisib for PIK3CA -Mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940. .
   PubMed Web of Science ®Google Scholar
• Andre F, Ciruelos E.M, Juric D, et al. Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC). ESMO. 2020;31(Suppl_4): S1142-S1215.
   Google Scholar
• Rugo HS, Ruiz Borrego M, Chia SKL, et al. Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA- mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): first interim BYLieve study results. J Clin Oncol. 2019;37(15_suppl):1040.
   Web of Science ®Google Scholar
• Rugo HS, André F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020;31(8):1001–1010. .
   PubMed Web of Science ®Google Scholar
• Hong R, Edgar K, Song K, et al. Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies [Internet]. In: Poster Discussion Abstracts. American Association for Cancer Research, Chicago IL USA; 2018 [cited 2020 Aug 18]. p. PD4-14-PD4-14. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS17-PD4-14
   Google Scholar
• Jhaveri K, Kalinsky K, Bedard P, et al. Abstract P1-19-46: a phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA -mutant HR+/HER2- breast cancer [Internet]. Ongoing Clin Trials. American Association for Cancer Research, Chicago IL USA; 2020 [cited 2020 Aug 18]. p. P1-19-46-P1-19–46. Available from. . ;. http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS19-P1-19-46
   Google Scholar
• Juric D, Kalinsky K, Oliveira M, et al. Abstract OT1-08-04: a first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA -mutant solid tumors [Internet]. Ongoing Clin Trials. American Association for Cancer Research, Chicago IL USA; 2020 [cited 2020 Aug 18]. p. OT1-08-04-OT1-08–04. Available from. . ;. http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS19-OT1-08-04
   Google Scholar
• Turner N, Dent R, O’Shaughnessy J, et al. 283MO Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): primary results from Cohort B of the IPATunity130 randomised phase III trial. Ann Oncol. 2020;31:S354–5.
   Web of Science ®Google Scholar
• Jones RH, Casbard A, Carucci M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2020;21(3):345–357. .
   PubMed Web of Science ®Google Scholar
• Wardell SE, Ellis MJ, Alley HM, et al. Efficacy of SERD/SERM Hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer. Clin Cancer Res. 2015;21(22):5121–5130. .
   PubMed Web of Science ®Google Scholar
• Kaklamani V, Bardia A, Wilks S, et al. Abstract PD7-07: final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer [Internet]. In: Poster Spotlight Session Abstracts. Chicago IL USA: American Association for Cancer Research; 2020 [cited 2020 Aug 18]. p. PD7-07-PD7-07. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS19-PD7-07
   Google Scholar
• Dickler M, Bardia A, Mayer I, et al. A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor-positive HER2-negative, advanced/metastatic breast cancer. Cancer Res. 2015;75S:AACR #CT231.
   Google Scholar
• André F, Cortés J. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat. 2015;150(1):1–8.
   PubMed Web of Science ®Google Scholar
• Musolino A, Campone M, Neven P, et al. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res. 2017;19(1):18. .
   PubMedGoogle Scholar
• Hui R, Pearson A, Cortes J, et al. Lucitanib for the Treatment of HR + /HER2 − metastatic breast cancer: results from the multicohort phase II FINESSE STUDY. Clin Cancer Res. 2020;26(2):354–363. .
   PubMed Web of Science ®Google Scholar
• Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase ii, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31(17):2128–2135.
   PubMed Web of Science ®Google Scholar
• Yeruva SLH, Zhao F, Miller KD, et al. E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. Npj Breast Cancer. 2018;4(1):1. .
   PubMedGoogle Scholar
• Rugo HS, Tredan O, Ro J, et al. Abstract PD5-1: results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer [Internet]. In: Poster Discussion Abstracts. Chicago IL USA: American Association for Cancer Research; 2015 [cited 2020 Aug 18]. p. PD5-1-PD5-1. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS14-PD5-1
   Google Scholar
• Lindeman GJ Bowen R Jerzak KJ et al. Results from VERONICA: a randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC). ASCO 2021.
   Google Scholar
• Pan W, Gu W, Nagpal S, et al. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem. 2015;61(3):514–522.
   PubMed Web of Science ®Google Scholar
• Eiger D, Wagner M, Pondé NF, et al. The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). Acta Oncol. 2020;59(6):723–725.
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987–3998. .
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy JA, Johnston S Harbeck N et al. Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer. San Antonio TX USA: SABCS 2020.
   Google Scholar
• Mayer EL, Dueck AC, Martin M, et al., Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22(2):212–222. .
   PubMed Web of Science ®Google Scholar
• Loibl S, Marmé F, Martin M, et al. Palbociclib for residual high-risk invasive HR-Positive and HER2-negative early breast cancer—the penelope-B trial. J Clin Oncol. 2021;39(14):1518–1530. .
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Fonseca Reis Silva DD, Machado Alessi JV, et al. Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives. ecancermedicalscience. Internet] 2016 [cited 2016 Apr 27];10. Available from. []:. http://www.ecancer.org/journal/10/full/609-neoadjuvant-endocrine-therapy-in-breast-cancer-current-role-and-future-perspectives.php
   Web of Science ®Google Scholar
• Charehbili A, Fontein DBY, Kroep JR, et al. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review. Cancer Treat Rev. 2014;40(1):86–92.
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. JNCI J Natl Cancer Inst. 2008;100(19):1380–1388. .
   Web of Science ®Google Scholar
• Ellis MJ, Suman VJ, Hoog J, et al. Randomized Phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–2349.
   PubMed Web of Science ®Google Scholar
• Goncalves R, Ma C, Luo J, et al. Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. Nat Rev Clin Oncol. 2012;9(4):223–229.
   PubMed Web of Science ®Google Scholar
• Khan QJ, O’Dea A, Bardia A, et al. Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial). J Clin Oncol. 2020;38(15_suppl):505. .
   Web of Science ®Google Scholar
• Sa H, Martin M, Mf P, et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase ii neoadjuvant study in HR + /HER2 − breast cancer. Clin Cancer Res. 2020;26(3):566–580. .
   PubMed Web of Science ®Google Scholar
• Ma CX, Gao F, Luo J, et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancer. Clin Cancer Res. 2017;23(15):4055–4065. .
   PubMed Web of Science ®Google Scholar
• Johnston S, Puhalla S, Wheatley D, et al. Randomized phase ii study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor–positive early breast cancer: PALLET trial. J Clin Oncol. 2019;37(3):178–189. .
   PubMed Web of Science ®Google Scholar
• Bachelot T, Dalenc F, Chabaud S, et al. Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer. Ann Oncol. 2021;32(4):574–575. .
   Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. .
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74.
   PubMed Web of Science ®Google Scholar
• Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676. .
   PubMed Web of Science ®Google Scholar
• Andre F, Su F, Solovieff N, et al. Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. J Clin Oncol. 2020;38(15_suppl):1009. .
   Google Scholar
• Prat A, Chaudhury A, Solovieff N, et al. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies. J Clin Oncol. 2021;39(13):1458–1467.
   PubMed Web of Science ®Google Scholar
• Portman N, Alexandrou S, Carson E, et al. Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocr Relat Cancer. 2019;26(1):R15–30.
   PubMed Web of Science ®Google Scholar